Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 4:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 33,144 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Bladder Cancer
Interventions: Polyphenon E, erlotinib hydrochloride, Erlotinib placebo, Polyphenon E; Dietary Supplement · Drug · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 5
States / cities: Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 1 more

Conditions: Alzheimer Disease
Interventions: COR388, Placebo; Drug
Lead sponsor: Cortexyme Inc.; Industry
Eligibility: 55 Years to 80 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 3
States / cities: San Diego, California • Orlando, Florida • Cincinnati, Ohio

Conditions: Autism Spectrum Disorder
Interventions: Cannabidivarin, Matched Placebo; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 5 Years to 18 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 2
States / cities: New York, New York • The Bronx, New York

Conditions: Attention Deficit Disorder With Hyperactivity, Marijuana Abuse
Interventions: Atomoxetine, placebo; Drug · Other
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 14 Years to 21 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: JNJ-42165279 (100 mg), Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Dementia, Alzheimer's Type, Alzheimer's Disease
Interventions: SAR448851, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 10
States / cities: Long Beach, California • Oakland, California • Naples, Florida + 7 more

Conditions: Tourette Syndrome, Chronic Tic Disorders
Interventions: Comprehensive Behavioral Intervention for Tics (CBIT), Computerized Response Inhibition Training, Computerized Placebo Cognitive Training; Behavioral
Lead sponsor: University of Wisconsin, Milwaukee; Other
Eligibility: 9 Years to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Chronic Hepatitis C
Interventions: Nitazoxanide, Placebo, Peginterferon alfa-2a, Ribavirin; Drug · Biological
Lead sponsor: Romark Laboratories L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 10
States / cities: Palo Alto, California • New Haven, Connecticut • Bay Pines, Florida + 6 more

Conditions: Eyebrow Hypotrichosis
Interventions: Platelet Rich Plasma Prep System, Saline; Device · Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Dementia
Interventions: Oral Fasudil 90 mg/day, Oral Fasudil 180 mg/day, Oral Placebo; Drug
Lead sponsor: Woolsey Pharmaceuticals; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: Stamford, Connecticut • Lakeland, Florida • Miami Lakes, Florida + 3 more

Conditions: Obesity, Weight Loss
Interventions: Lorcaserin HCl, Placebo; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Anal High Grade Squamous Intraepithelial Lesion, Anal Precancerous Condition, AIN 2/3, HPV Infection, Anal Dysplasia, HPV Disease
Interventions: Artesunate, Placebo; Drug
Lead sponsor: Frantz Viral Therapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: Hidradenitis Suppurativa
Interventions: Bimekizumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 505 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more

Conditions: Healthy Volunteers, Safety After Oral Intake
Interventions: Energy Drink A + Placebo Capsule, Placebo Drink + Moxifloxacin Capsule, Placebo Drink + Caffeine Capsule, Placebo Drink + Placebo Capsule, Energy Drink B, Control Product + Taurine, Control Product + Caffeine + Taurine, Lower Dose Energy Drink A; Dietary Supplement · Drug · Other
Lead sponsor: University of the Pacific; Other
Eligibility: 18 Years to 40 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Stockton, California

Conditions: Nicotine Dependence
Interventions: Varenicline, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 60 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Weight Loss, Mood
Interventions: Lactobacillus plantarum, Placebo; Dietary Supplement
Lead sponsor: 3 Waves Wellness; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Plymouth, Massachusetts

Conditions: Infertility of Uterine Origin
Interventions: AMD3100, Normal saline, dilation and curettage; Drug · Procedure
Lead sponsor: Reproductive Medicine Associates of New Jersey; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: San Francisco, California • Basking Ridge, New Jersey • Philadelphia, Pennsylvania

Conditions: Postoperative Pain, Laparoscopic Hysterectomy, Nerve Block, Quadratus Lumborum Block
Interventions: Quadratus Lumborum Block (QLB), Quadratus lumborum block, Local Anesthetic Solution; Drug
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years and older · Female only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pain
Interventions: OraVescent Fentanyl; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 21
States / cities: Hot Springs, Arkansas • Los Gatos, California • Oxnard, California + 16 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: GSK233705 12.5mcg, GSK233705 25mcg, GSK233705 50mcg, GSK233705 100mcg, GSK233705 200mcg, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 576 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 25
States / cities: Jasper, Alabama • Glendale, Arizona • Fountain Valley, California + 21 more

Conditions: Covid19
Interventions: Fluoxetine, Placebo; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Inflammation, Systemic Lupus Erythematosus
Interventions: NNC 0151-0000-0000, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Lake Success, New York

Conditions: Type1 Diabetes Mellitus, Hypoglycemia Unawareness
Interventions: Amitriptyline, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 21 Years to 60 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Sexual Dysfunctions, Psychological
Interventions: flibanserin, flibanserin 50mg, flibanserin 100mg, placebo; Drug
Lead sponsor: Sprout Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 1,584 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 64
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 59 more

Search by objective public record fields.

Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer

A Multiple Ascending Dose Study of COR388

Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)

Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder

The Effects of JNJ-42165279 on the Neural Basis of Anxiety Disorders in Healthy Male Volunteers

A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease

Developing Cognitive Training for Tourette Syndrome

Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients

Platelet-rich Plasma for Eyebrows

Fasudil fOr redUcing elopemeNt and Spatial Disorientation

Lorcaserin in Obesity: Identification of CNS Targets Using fMRI

Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Effects of Energy Drinks on Cardiovascular Endpoints

Effects of Varenicline on Smoking Reminders

Effects of Lactobacillus Plantarum KABP-51 Probiotic on Body Composition, Microbiome and Mood in Healthy Overweight Adults

Endometrial Rejuvenation Study

Impact of Preoperative Quadratus Lumborum Block on Postoperative Opioid Consumption After Laparoscopic Hysterectomy

Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain

Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)

An Investigation of NNC 0151-0000-0000 in Subjects With Systemic Lupus Erythematosus (SLE)

Amitriptyline in Treating Hypoglycemia

Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder